ImmunoCard® C. difficile GDH

Catalog Number: 716050

Product Description

A Rapid Enzyme Immunoassay for the Detection of Clostridium difficile GDH Antigen in Stool Specimens.

ImmunoCard® C. difficile GDH is a rapid qualitative enzyme immunoassay screening test to detect Clostridium difficile antigen, glutamate dehydrogenase, in fecal specimens from persons suspected of having C. difficile infection (CDI). This test does not distinguish between toxigenic and non-toxigenic strains of C. difficile. Samples from patients that produce positive results with this test must be further tested with an assay designed to detect toxigenic C. difficile strains and assist with the diagnosis of CDI.

Immuno<em>Card</em>&reg; <em>C. difficile</em> GDH

Double click on above image to view full picture

Zoom Out
Zoom In


Related Products

  • Details

    Product Specification 

    Catalog Number: 716050
    Assay Format: Rapid Qualitative Immuno Enzymatic Assay in card format
    Kit Size: 50 tests
    Specimen Type: Stool (unpreserved)
    Sensitivity: 97.6%
    Specificity: 87%
    Time to Results (TAT): 25 min
    Kit Storage Requirements: 2-8°C
    Shelf Life: 18 months
    Manufacturer: Meridian Bioscience, Inc.
    GMDN: 30714
    CE: YES
    FDA: YES
    Availability: European Union
    Other countries: Please Contact Us or visit our Distributor page.

    Customer Reviews

    "Previously our laboratory used QCC from TechLab, Alere as the cornerstone of our Clostridrium difficile routine diagnostic testing. We decided two years ago to switch to the Meridian Bioscience CDIFF ABSOLUTE algorithm, which combines two steps, namely, the ImmunoCard GDH common antigen screen, which screens out negative samples effectively, and the illumigene molecular step which is used to confirm GDH positive stool samples. CDIFF ABSOLUTE has proven itself a more rapid, more cost effective and more efficient algorithmic approach with superior accuracy, compared to QCC in our experience."

    Dr Mulongo, CEBIODO, Brussels, Belgium

    “For our CDI lab diagnosis we selected the CDIFF ABSOLUTE strategy (incorporating ImmunoCard GDH as an initial screen given its high NPV, followed by illumigene®) as our routine method of choice. CDIFF ABSOLUTE has been adapted for the lab for the past 2 years.
    This benefits us in a number of ways: very fast assay results, which enables us to report back to the clinician very quickly so that both therapeutic and patient isolation/no-isolation decisions can be made rapidly and appropriately. The illumigene® platform is both robust and easy to use, with minimal training requirements and also in comparison to PCR, as no special room conditions are required, the illumigene can be used on weekends and with versatility.
    Previously, we deployed QCC + PCR in the lab and beforehand VIDAS A+B was used, however, from a logistical, turnaround time and accuracy perspective, illumigene® has proven itself to be superior to both these approaches.”

    Dr JM Senterre, CHR Citadelle, Liege, BELGIUM

  • You may also be interested in the following product(s)

    Alethia™ <em>C. difficile</em> / illumigene <em>C. difficile</em> by Meridian Bioscience

    Alethia™ C. difficile / illumigene C. difficile by Meridian Bioscience

    Premier® <em>C. difficile</em> GDH

    Premier® C. difficile GDH